Salute e Benessere
Annual Report 2024 released by Scantox Group
With the acquisitions made in 2024, Scantox is now able to deliver a full range of services - from early-stage lead identification and regulatory-requested safety studies through to on-market drug support.
"We have in 2024 continued to demonstrate our commitment to expanding both service offerings and geographic reach, serving as a "one-stop-shop" to foster deeper collaboration, whilst remaining steadfast to our core value: being a trusted partner that delivers high-quality, science-led interactions from first contact to final report," Christensen explains.
"Going forward, Scantox will continue to grow our business with both new and existing clients - from virtual biotech companies to the largest global pharma companies - by offering an ever-expanding portfolio of high-quality services. Simultaneously, we are investing in our operations to digitize processes and introduce new models where they benefit our clients."
Scantox is a leading preclinical contract research organization (CRO) accelerating the drug discovery and development process for clients worldwide with a service portfolio covering all main areas within Discovery, Regulatory Toxicology and Analytical Services. The company is headquartered in Denmark , with subsidiaries in Denmark , Sweden , Austria and the UK.
Read the full report: https://scantox.com/about-scantox/annual-report/
Logo: https://mma.prnewswire.com/media/2674623/ScantoGroup_Logo.jpg
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/annual-report-2024-released-by-scantox-group-302439537.html